First Tracks Q1 net loss $50.5M; launched with $180M cash; ANB033 Phase 1b data expected Q4 2026

First Tracks Biotherapeutics, Inc.

Net loss of $50.5M for Q1 2026 vs $47.2M in Q1 2025; R&D expense $34.0M (down from $41.5M).
Launched on April 20 with $180M cash and a two-year runway to fund ANB033 and other programs.
ANB033 Phase 1b trials in celiac disease and eosinophilic esophagitis ongoing; top-line data Q4 2026 and mid-2027.
Rosnilimab had productive End-of-Phase 2 FDA meeting for RA; company assessing strategic options.
G&A expense rose to $18.9M from $9.8M due to separation costs and stock compensation.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

First Tracks Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $50.5 million for the three months ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $50.5 million for the three months ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

Browse all earnings releases →

First Tracks Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.